Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma.
Takashi NakanoHerbert EradatAxel FlorschützAndreas HochhausTomasz WrobelJan WalewskiWanda Knopinska-PoslusznyAbraham S KanateEwa Lech-MarandaUta BrunnbergSurya ChitraTina G NielsenGila SellamMahesh ShivhareIzidore S LossosPublished in: Journal of cancer research and clinical oncology (2022)
NCT02729896; Date of registration: April 6, 2016.